Molecular biology of vasoactive substances

血管活性物质的分子生物学

基本信息

  • 批准号:
    06044129
  • 负责人:
  • 金额:
    $ 2.82万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for international Scientific Research
  • 财政年份:
    1994
  • 资助国家:
    日本
  • 起止时间:
    1994 至 1995
  • 项目状态:
    已结题

项目摘要

Brain natriuretic peptide (BNP) mRNA increased and reached a maximal level within 1 h in a model of cardiac hypertrophy using cultured neonatal ratventricular cardiocytes, which was completely diminished by a transcriptional inhibitor. The promotor activity of the cloned 5'-flanking region of human BNP gene was reduced to 30% when the CT-rich sequences (-1288 to -1095) were deleted. The BNP gene was assigned to human chromosome 1. Two novel transcripts of the human endothelin-A receptor (ET-AR) gene contained deletions of 199 bp and 327 bp were demonstrated using RT-PCR.The deleted sequences corresponded to exon 4 and exons 3 and 4, respectively, indicating these ET-AR transcripts result from alternative RNA splicing. The putative negative regulatory region was located between -453 and -225 of mouse angiotensin II type 2 (AT_2) receptor gene, in which the interferon regulatory factor (IRF) binding motif was identified. IRF-2 attenuated the AT2 receptor expression in both growing and confluent R3T3 cells, whereas IRF-1 enhanced AT2 receptor expression in the confluent cells only. The human prostacyclin receptor gene spanned approximately 7.0 kb and was composed of three exons, which was assigned to chromosome 19. The transcription initiation sites were mapped 870-872 bp upstream to the ATG start codon. The 1.2-kb 5'-flanking region lacked conventional TATA and CCAAT boxes, but it contained several cis-acting regulatory elements including an inverted CCAAT box and two copies of SP-1 binding sites.
用培养的新生大鼠心室肌细胞建立心肌肥厚模型,脑钠肽(BNP)mRNA在1小时内升高并达到最高水平,而转录抑制剂可完全抑制BNP mRNA的表达。克隆的人BNP基因5 '侧翼区的启动子活性在富含CT的序列(-1288 ~-1095)缺失后降低到30%。BNP基因定位于人类1号染色体。用RT-PCR方法检测到两个新的人内皮素A受体(ET-AR)基因转录本,分别缺失199 bp和327 bp,缺失序列分别对应于外显子4和外显子3、4,表明这两个ET-AR基因转录本是RNA选择性剪接的产物。该负调控区位于小鼠血管紧张素Ⅱ 2型(AT_2)受体基因的-453 ~-225之间,其中存在干扰素调节因子(IRF)结合基序。IRF-2减弱了生长和融合的R3 T3细胞中的AT 2受体表达,而IRF-1仅增强了融合细胞中的AT 2受体表达。人前列环素受体基因跨越约7.0 kb,由三个外显子组成,被分配到19号染色体。转录起始位点定位在ATG起始密码子上游870-872 bp处。1.2kb的5 '侧翼区缺乏传统的TATA和CCAAT盒,但它含有几个顺式作用调控元件,包括一个反向的CCAAT盒和两个拷贝的SP-1结合位点。

项目成果

期刊论文数量(26)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Y.Miyamoto, T.Yoshimasa, H.Arai, K.Takaya, Y.Ogawa, H.Itoh, K.Nakao: "Alternative RNA splicing of human endothelin-A receptor generates multiple transcripts." Biochemical J.313. 795-801 (1996)
Y.Miyamoto、T.Yoshimasa、H.Arai、K.Takaya、Y.Okawa、H.Itoh、K.Nakao:“人内皮素 A 受体的选择性 RNA 剪接会生成多个转录本。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
M.Mukoyama,M.Horiuchi,M.Nakajima,R.E.Prattt,V.J.Dzau: "Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells." Mol.Cell.Endocrinol.112. 61-68 (1995)
M.Mukoyama、M.Horiuchi、M.Nakajima、R.E.Prattt、V.J.Dzau:“在 293 细胞中稳定表达的大鼠 2 型血管紧张素 II 受体的表征。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
M.Horiuchi, G.Koike, T.Yamada, M.Mukoyama, M.Nakajima, V.J.Dzau: "The growth-dependent expression of angiotensin II type 2 receptor is regulated by transcription factors interferon regulatory factor-1 and -2." J.Biol.Chemist.270. 20225-20230 (1995)
M.Horiuchi、G.Koike、T.Yamada、M.Mukoyama、M.Nakajima、V.J.Dzau:“血管紧张素 II 2 型受体的生长依赖性表达受转录因子干扰素调节因子-1 和 -2 的调节。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
O.Nakagawa et al.: "Molecular cloning of human prostacyclin receptor cDNA and its gene expression on cardiovascular system." Circulation. 90. 1643-1647 (1994)
O.Nakakawa 等人:“人前列环素受体 cDNA 的分子克隆及其对心血管系统的基因表达”。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
I.Kishimoto et al.: "Natriuretic peptide clearance receptor is trnascriptionally down-regulated by β_2-adrenergic stimulation in vascular smooth muscle cells." J.Biol.Chem.269. 28300-28308 (1994)
I.Kishimoto 等人:“血管平滑肌细胞中的 β_2-肾上腺素刺激可转录下调利钠肽清除受体。”J.Biol.Chem.269(1994)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAKAO Kazuwa其他文献

NAKAO Kazuwa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NAKAO Kazuwa', 18)}}的其他基金

Development and analysis of model rats for diseases of endocrinology and metabolism
内分泌代谢疾病模型大鼠的建立及分析
  • 批准号:
    23659476
  • 财政年份:
    2011
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Physiological Function of Hormones Derived from Mesenchymal Cells and Its Failure
间充质细胞激素的生理功能及其失效
  • 批准号:
    21229013
  • 财政年份:
    2009
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
Translational research and development of novel diagnostic/therapeutic modalities for metabolic syndrome based on adipocyte endocrinology and adiposcience
基于脂肪细胞内分泌学和脂肪科学的代谢综合征新型诊断/治疗方式的转化研究和开发
  • 批准号:
    16109007
  • 财政年份:
    2004
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
Molecular Basis of Centrally-controled Energy Homeostasis -Focusing on Leptin Resistance-
中央控制能量稳态的分子基础 - 关注瘦素抵抗 -
  • 批准号:
    13307033
  • 财政年份:
    2001
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Clinical implication of cardiovascular hormones
心血管激素的临床意义
  • 批准号:
    10307026
  • 财政年份:
    1998
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A).
Molecular Study on Physiological and Clinical Significance of Adrenomedullin
肾上腺髓质素生理和临床意义的分子研究
  • 批准号:
    10218204
  • 财政年份:
    1998
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
New Animal Models Of Leaness And Obesity by Genetic Engineering and its Application to Therapy
基因工程瘦和肥胖的新动物模型及其在治疗中的应用
  • 批准号:
    09557080
  • 财政年份:
    1997
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular and Clinical Study of Cardiovascular Hormones
心血管激素的分子和临床研究
  • 批准号:
    08044272
  • 财政年份:
    1996
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
Development of novel mouse models deficient in vasoactive substances-Clinical implication of the natriuretic peptide family and its application to gene therapy-
血管活性物质缺乏的新型小鼠模型的开发-利尿钠肽家族的临床意义及其在基因治疗中的应用-
  • 批准号:
    07557072
  • 财政年份:
    1995
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Molecular Biology of Vasoactive Substances
血管活性物质的分子生物学
  • 批准号:
    06404037
  • 财政年份:
    1994
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)

相似海外基金

MICA: A Developmental Trial of Personalised Medicine for Repurposing Zibotentan, a Selective Endothelin A Receptor Blocker, in Microvascular Angina.
MICA:重新利用 Zibotentan(一种选择性内皮素 A 受体阻滞剂)治疗微血管心绞痛的个性化医疗开发试验。
  • 批准号:
    MR/S018905/1
  • 财政年份:
    2019
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Research Grant
MICA: Evaluation of the selective endothelin A-receptor antagonist zibotentan as a treatment for renal disease in systemic sclerosis (scleroderma)
MICA:选择性内皮素 A 受体拮抗剂 zibotentan 治疗系统性硬化症(硬皮病)肾脏疾病的评估
  • 批准号:
    MR/K015230/1
  • 财政年份:
    2013
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Research Grant
The role of kinases on multiple G proteins activation by endothelin A receptor
激酶在内皮素 A 受体激活多种 G 蛋白中的作用
  • 批准号:
    20790086
  • 财政年份:
    2008
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemodynamic regulation and hormonal changes during hemorrhage with and without simultaneous Angeotensin II and for Endothelin A receptor blockade in conscious and anaesthetized Beagle dogs.
在清醒和麻醉的比格犬中,同时使用和不使用血管紧张素 II 以及内皮素 A 受体阻断时出血期间的血流动力学调节和激素变化。
  • 批准号:
    5272374
  • 财政年份:
    2001
  • 资助金额:
    $ 2.82万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了